These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31547750)

  • 1. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
    Karaağaç M; Eryılmaz MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A; Koch A; Grünwald V
    Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and fatal acute heart failure induced by pazopanib.
    van Marcke C; Ledoux B; Petit B; Seront E
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26336188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
    Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
    Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
    Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
    J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
    Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
    J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute heart failure following pazopanib treatment: a literature review featuring two case reports.
    Kertmen N; Kavgaci G; Yildirim HC; Dizdar O
    Anticancer Drugs; 2024 Mar; 35(3):302-304. PubMed ID: 38018812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma　- A Single Institute Analysis.
    Wang X; Nakano K; Shiga T; Ohmoto A; Oyakawa T; Ebihara A; Sato Y; Fukuda N; Nishizawa M; Urasaki T; Ono M; Yunokawa M; Tomomatsu J; Takahashi S
    Circ J; 2024 Jan; 88(2):228-233. PubMed ID: 35314578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
    Huang PW; Chou WC; Shen WC; Hung CY; Huang KG; Su YL; Lu CH; Liu CT; Chang YS; Liau CT
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):353-360. PubMed ID: 29900662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib and soft-tissue sarcomas. Too toxic.
    Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumothorax in lung metastasis of advanced soft tissue sarcoma patients treated with oral pazopanib.
    Sarkar S; Mishra PK; Mukhopadhyay S; Sen S; Biswas B
    Indian J Cancer; 2024 Apr; 61(2):278-281. PubMed ID: 38090966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal heart failure in a young adult female sarcoma patient treated with pazopanib.
    Soomers VLMN; Desar IME; van Erp NP; Verwiel J; Kaal SEJ; van der Graaf WTA
    Acta Oncol; 2017 Sep; 56(9):1233-1234. PubMed ID: 28537442
    [No Abstract]   [Full Text] [Related]  

  • 16. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
    Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
    J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
    Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
    BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.
    Delyon J; Porcher R; Battistella M; Meyer N; Adamski H; Bertucci F; Guillot B; Jouary T; Leccia MT; Dalac S; Mortier L; Ghrieb Z; Da Meda L; Vicaut E; Pedeutour F; Mourah S; Lebbe C
    J Invest Dermatol; 2021 Apr; 141(4):761-769.e2. PubMed ID: 32956651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
    Kasper B; Hohenberger P
    Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.